Press Resease

Parkinson’s Disease Treatment Market - Global Industry Analysis

Parkinson’s Disease Treatment Market - By Therapeutic Class (Dopamine Precursors, Monoamine Oxidase B Inhibitors, Catechol-O-Methyl Transferase Inhibitors, Carbidopa/Levodopa, Dopamine Agonists, and Other Therapeutic Classes), By Medical Devices (Deep Brain Stimulation Devices and Carbidopa/Levodopa Enteral Suspension Delivery Devices), By Patient Care Setting (Clinics and Hospitals), By Distribution Channel (Online Pharmacies, Retail Pharmacies, Drug Stores, and Hospital Pharmacies), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

Published Date: 22-Sep-2020 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2854 Status : Published

Global Parkinson’s Disease Treatment market, which is projected at 8.38 (USD Billion) by 2026, is slated to register a CAGR of nearly 7.5% over 2020-2026.

Description

The global Parkinson’s disease Treatment market, which is projected at 8.38 (USD Billion) by 2026, is slated to register a CAGR of nearly 7.5% over 2020-2026. The report offers valuation and analysis of Parkinson’s disease Treatment market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2016 to 2019 along with a forecast from 2020 to 2026 based on value (USD Billion).

Introduction

Parkinson is chronic neurodegenerative disorder that affects the body movements and results in tremor in hands, stiffness in movements of body parts & muscles, bradykinesia, and postural instability. Other symptoms of the disease include depression, dysphagia, emotional changes, constipation, urine problems, dysarthria, disturbed sleep, and skin problems. The disease has notable impact on mobility as well as muscle control of the patients.  Furthermore, the disease is influenced by both motor as well as non-motor characteristics. For instance, motor symptoms of the disease are attributed to loss of striatal dopaminergic neurons and non-motor symptoms of the disorder supports loss of neurons in non-dopaminergic areas of nervous system.

According to NCBI, at present, there are no disease altering therapies for the disease. However, medical management makes use of dopaminergic medicines and deep brain stimulation to treat patients having Parkinson disease. Reportedly, levodopa therapy is the most commonly used for treating Parkinson disorder in early stages and can help in reducing tremor, bradykinesia, and muscle rigidity to a large extent in the patients. Moreover, levodopa is combined with dopa-decarboxylase inhibitor to restrict the side effects like nausea. For the record, dopamine agonists like rotigotine or ropinirole are also popular medicines used for treating Parkinson disease. In addition to this, monoamine oxidase B inhibitors like selegiline and rasagiline as well as catecho-O-Methyltransferase inhibitors like entacapone are utilized for reducing metabolism of dopamine.  Apparently, these therapies have the ability of restoring dopaminergic activities in striatum along with bringing enhancements in motor features of Parkinson disorder.

Market Growth Dynamics

Massive utilization of L-Dopa, a symptomatic dopamine replacement treatment and nigrostriatal system will boost the market trends. In addition to this, the shifting of research activities from symptomatic treatment to Parkinson disorder modifying treatment will create lucrative growth avenues for Parkinson’s disease treatment industry over the forthcoming years. Large-scale research and clinical trials are under way for bringing a revolution in symptomatic treatment of Parkinson’s disease and this can embellish the business growth. Apart from this, vital breakthroughs in development and clinical testing of drugs for providing modification in the Parkinson’s disease are projected to contribute substantially towards the growth of Parkinson’s disease treatment industry over the years to come. Reportedly, cell-based approaches and viral gene-delivery approaches are also the best available alternatives for treating Parkinson Disease and this will help the market reach new horizons of growth within the next couple of years.

Furthermore, ongoing genetic & neuropathological research is predicted to provide new insights into the understanding of the Parkinson disorder and this will enhance the market earnings in the coming decade. Citing an instance, in 1997, a new gene mutation for alpha-synuclein protein causing autosomal dominant Parkinson disorder was discovered. Additionally, use of non-dopaminergic drugs like amantadine and anticholinergic has proved to offer symptomatic relief in early stages of Parkinson disease treatment. Anticholinergic drugs like benztropine and trihexphenidyl are used in young patients impacted due to tremors and these drugs are used along with levodopa.

Additionally, the Braak staging hypothesis that Parkinson disorder begins in either olfactory bulb or gastrointestinal system has paved a way continuum of researchers in the domain of Parkinson disease treatment, thereby driving the growth of the market in the coming years. Furthermore, use of adjunctive therapy and anti-glutamatergic medicines for treating Parkinson disease will proliferate the expansion of the Parkinson’s disease treatment market over the forthcoming years.

Asia Pacific Market To Record Highest Growth Rate Over 2020-2026

The growth of the industry in the sub-continent over the estimated timespan is owing to favorable government policies and surge in the research activities pertaining to the treatment of Parkinson disease in the countries like India, Japan, and China. In addition to this, huge sale of generic medicines and surge in the aging population prone to the Parkinson disorder will further prop up the growth of the Parkinson’s disease market in Asia Pacific zone.

Key players profiled in the report are BIAL Pharm; Novartis AG; Salix Pharmaceuticals; GlaxoSmithKline Plc.; Impax Laboratories, Inc.; Daiichi Sankyo; Wockhardt Limited; Mylan N.V.; Cipla Inc.; Teva Pharmaceutical Industries Ltd.; Par Pharmaceutical; Orion Corporation; and Apotex Inc.

The global Parkinson’s disease treatment market is segmented as follows:

By therapeutic class:

  • Dopamine precursors
  • Monoamine oxidase B inhibitors (MAO-B inhibitors)
  • Catechol-O-methyl transferase (COMT) inhibitors
  • Dopamine agonists (non-ergoline)
  • Carbidopa/Levodopa
  • Other Therapeutic Classes

By medical devices:

  • Deep Brain Stimulation (DBS) Devices
  • Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices

By patient care setting:

  • Clinics
  • Hospitals

By distribution channel:

  • Online pharmacies
  • Retail pharmacies
  • Hospital pharmacies
  • Drug stores

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Parkinson’s Disease Treatment Market , 2016–2026 (USD Billion)
    • 2.2. Parkinson’s Disease Treatment Market : Snapshot
  • Chapter 3. Global Parkinson’s Disease Treatment Market – Industry Analysis
    • 3.1. Parkinson’s Disease Treatment Market : Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Ongoing genetic & neuropathulogical research is predicted to provide new insights into the understanding of the Parkinson disorder and this will enhance the market earnings in the coming decade.
      • 3.2.2. The Braak staging hypothesis that Parkinson disorder begins in either ulfactory bulb or gastrointestinal system has paved a way continuum of researchers in the domain of Parkinson disease treatment, thereby driving the growth of the market in the coming years.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Therapeutic Class
      • 3.4.2. Market attractiveness analysis By Medical Devices
      • 3.4.3. Market attractiveness analysis By Patient Care Setting
      • 3.4.4. Market attractiveness analysis By Distribution Channel
  • Chapter 4. Global Parkinson’s Disease Treatment Market – Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Parkinson’s Disease Treatment Market : company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Parkinson’s Disease Treatment Market – Therapeutic Class Analysis
    • 5.1. Global Parkinson’s Disease Treatment Market overview: By Therapeutic Class
      • 5.1.1. Global Parkinson’s Disease Treatment Market share, By Therapeutic Class , 2019 and 2026
    • 5.2. Dopamine Precursors
      • 5.2.1. Global Parkinson’s Disease Treatment Market By Dopamine Precursors, 2016–2026 (USD Billion)
    • 5.3. Monoamine Oxidase B Inhibitors
      • 5.3.1. Global Parkinson’s Disease Treatment Market By Monoamine Oxidase B Inhibitors, 2016–2026 (USD Billion)
    • 5.4. Catechul-O-Methyl Transferase Inhibitors
      • 5.4.1. Global Parkinson’s Disease Treatment Market By Catechul-O-Methyl Transferase Inhibitors, 2016–2026 (USD Billion)
    • 5.5. Carbidopa/Levodopa
      • 5.5.1. Global Parkinson’s Disease Treatment Market By Carbidopa/Levodopa, 2016–2026 (USD Billion)
    • 5.6. Dopamine Agonists
      • 5.6.1. Global Parkinson’s Disease Treatment Market By Dopamine Agonists, 2016–2026 (USD Billion)
    • 5.7. Other Therapeutic Classes
      • 5.7.1. Global Parkinson’s Disease Treatment Market By Other Therapeutic Classes, 2016–2026 (USD Billion)
  • Chapter 6. Global Parkinson’s Disease Treatment Market – Medical Devices Analysis
    • 6.1. Global Parkinson’s Disease Treatment Market overview: By Medical Devices
      • 6.1.1. Global Parkinson’s Disease Treatment Market share, By Medical Devices , 2019 and 2026
    • 6.2. Deep Brain Stimulation Devices
      • 6.2.1. Global Parkinson’s Disease Treatment Market By Deep Brain Stimulation Devices , 2016–2026 (USD Billion)
    • 6.3. Carbidopa/Levodopa Enteral Suspension Delivery Devices
      • 6.3.1. Global Parkinson’s Disease Treatment Market By Carbidopa/Levodopa Enteral Suspension Delivery Devices, 2016–2026 (USD Billion)
  • Chapter 7. Global Parkinson’s Disease Treatment Market – Patient Care Setting Analysis
    • 7.1. Global Parkinson’s Disease Treatment Market overview: By Patient Care Setting
      • 7.1.1. Global Parkinson’s Disease Treatment Market share, By Patient Care Setting , 2019 and 2026
    • 7.2. Clinics
      • 7.2.1. Global Parkinson’s Disease Treatment Market By Clinics, 2016–2026 (USD Billion)
    • 7.3. Hospitals
      • 7.3.1. Global Parkinson’s Disease Treatment Market By Hospitals, 2016–2026 (USD Billion)
  • Chapter 8. Global Parkinson’s Disease Treatment Market – Distribution Channel Analysis
    • 8.1. Global Parkinson’s Disease Treatment Market overview: By Distribution Channel
      • 8.1.1. Global Parkinson’s Disease Treatment Market share, By Distribution Channel , 2019 and 2026
    • 8.2. Online Pharmacies
      • 8.2.1. Global Parkinson’s Disease Treatment Market By Online Pharmacies, 2016–2026 (USD Billion)
    • 8.3. Retail Pharmacies
      • 8.3.1. Global Parkinson’s Disease Treatment Market By Retail Pharmacies 2016–2026 (USD Billion)
    • 8.4. Drug Stores
      • 8.4.1. Global Parkinson’s Disease Treatment Market By Drug Stores 2016–2026 (USD Billion)
    • 8.5. Hospital Pharmacies
      • 8.5.1. Global Parkinson’s Disease Treatment Market By Hospital Pharmacies 2016–2026 (USD Billion)
  • Chapter 9. Company Profiles
    • 9.1. Novartis AG
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. GlaxoSmithKline Plc
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Impax Laboratories, Inc.
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. Teva Pharmaceutical Industries Ltd.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. BIAL Pharm
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Development
    • 9.6. Par Pharmaceutical
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Development
    • 9.7. Orion Corporation
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Development
    • 9.8. Daiichi Sankyo
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Development
    • 9.9. Mylan N.V.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Development
    • 9.10. Wockhardt Limited
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product Portfolio
      • 9.10.4. Business Strategy
      • 9.10.5. Recent Development
    • 9.11. Cipla Inc.
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Product Portfolio
      • 9.11.4. Business Strategy
      • 9.11.5. Recent Development
    • 9.12. Salix Pharmaceuticals
      • 9.12.1. Overview
      • 9.12.2. Financials
      • 9.12.3. Product Portfolio
      • 9.12.4. Business Strategy
      • 9.12.5. Recent Development
    • 9.13. Apotex Inc.
      • 9.13.1. Overview
      • 9.13.2. Financials
      • 9.13.3. Product Portfolio
      • 9.13.4. Business Strategy
      • 9.13.5. Recent Development

Methodology


Frequently Asked Questions

Massive utilization of L-Dopa, a symptomatic dopamine replacement treatment and nigrostriatal system will boost the market trends. In addition to this, the shifting of research activities from symptomatic treatment to Parkinson disorder modifying treatment will create lucrative growth avenues for Parkinson’s disease treatment industry over the forthcoming years. Large-scale research and clinical trials are under way for bringing a revolution in symptomatic treatment of Parkinson’s disease and this can embellish the business growth.

According to Zion Market Research report, The global Parkinson’s disease Treatment market, which is projected at 8.38 (USD Billion) by 2026, is slated to register a CAGR of nearly 7.5% over 2020-2026.

Asia Pacific is likely to make noteworthy contributions towards overall market revenue. The growth of the industry in the sub-continent over the estimated timespan is attributed to favorable government policies and surge in the research activities pertaining to the treatment of Parkinson disease in the countries like India, Japan, and China. Apparently, humungous presence of generic medicine supplies in the region and surge in the aging population prone to the Parkinson disorder will further prompt the growth of the Parkinson’s disease market in Asia Pacific zone.

The key players profiled in the report include BIAL Pharm; Novartis AG; Salix Pharmaceuticals; GlaxoSmithKline Plc.; Impax Laboratories, Inc.; Daiichi Sankyo; Wockhardt Limited; Mylan N.V.; Cipla Inc.; Teva Pharmaceutical Industries Ltd.; Par Pharmaceutical; Orion Corporation; and Apotex Inc. With new players entering the market, it has become highly competitive and existing players are focusing on product innovations keeping the cost of product reasonable with a view to acquire desired profits.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social